Back to top
more

Pacira BioSciences (PCRX)

(Delayed Data from NSDQ)

$16.57 USD

16.57
466,978

-0.03 (-0.18%)

Updated Nov 1, 2024 03:59 PM ET

After-Market: $16.58 +0.01 (0.06%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value B Growth C Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (89 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Onconova (ONTX) to Report Q2 Earnings: What's in the Offing?

by Zacks Equity Research

Investors will focus on pipeline updates when Onconova (ONTX) reports Q2 results.

Teva (TEVA) to Report Q2 Earnings: What's in the Cards?

by Zacks Equity Research

On Teva's (TEVA) second-quarter conference call, investors will look for updates on the extent to which the coronavirus pandemic may have impacted sales of its products

Will Pacira (PCRX) Beat Estimates Again in Its Next Earnings Report?

by Zacks Equity Research

Pacira (PCRX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

3 Reasons Why Pacira (PCRX) Is a Great Growth Stock

by Zacks Equity Research

Pacira (PCRX) possesses solid growth attributes, which could help it handily outperform the market.

Zoetis (ZTS) Hits 52-Week High, Can the Run Continue?

by Zacks Equity Research

Zoetis (ZTS) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Top Ranked Momentum Stocks to Buy for July 21st

by Zacks Equity Research

Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, July 21st

Vaxart (VXRT) Catches Eye: Stock Jumps 7.9%

by Zacks Equity Research

Vaxart (VXRT) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.

Zacks.com featured highlights include: Nautilus, Ameresco, Canadian Solar, Emergent BioSolutions and Pacira BioSciences

by Zacks Equity Research

Zacks.com featured highlights include: Nautilus, Ameresco, Canadian Solar, Emergent BioSolutions and Pacira BioSciences

Nalak Das headshot

5 Stocks With Recent Price Strength Despite Market Volatility

by Nalak Das

Investors target stocks that are witnessing a bullish run. Actually, stocks seeing price strength have a high chance of carrying the momentum forward.

Entasis Therapeutics (ETTX) Jumps: Stock Rises 5.4%

by Zacks Equity Research

Entasis Therapeutics (ETTX) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.

Otonomy (OTIC) Catches Eye: Stock Jumps 9.1%

by Zacks Equity Research

Otonomy (OTIC) saw a big move last session, as its shares jumped more than 9% on the day, amid huge volumes.

Verrica (VRCA) in Focus: Stock Moves 8.9% Higher

by Zacks Equity Research

Verrica (VRCA) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.

Top Ranked Momentum Stocks to Buy for July 10th

by Zacks Equity Research

Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, July 10th

The Zacks Analyst Blog Highlights: Alpine Immune Sciences, Actinium Pharmaceuticals, Pacira BioSciences and Translate Bio

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Alpine Immune Sciences, Actinium Pharmaceuticals, Pacira BioSciences and Translate Bio

Pacira (PCRX) Provides Preliminary Results for Second Quarter

by Zacks Equity Research

Pacira (PCRX) reports preliminary results for the second quarter of 2020. The company's product sales are hurt by the COVID-19 pandemic. The stock fell in pre-market trading.

4 Small Drug Stocks Worth Betting on Amid Coronavirus Woes

by Zacks Equity Research

Here we discuss four small stocks from the drug sector, which hold potential for a good run amid the coronavirus crisis.

Will Pacira BioSciences Continue to Surge Higher?

by Zacks Equity Research

As of late, it has definitely been a great time to be an investor of Pacira BioSciences

Pacira (PCRX) Hits 52-Week High, Can the Run Continue?

by Zacks Equity Research

Pacira (PCRX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Why Is Pacira (PCRX) Up 14.6% Since Last Earnings Report?

by Zacks Equity Research

Pacira (PCRX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

PCRX vs. ZTS: Which Stock Should Value Investors Buy Now?

by Zacks Equity Research

PCRX vs. ZTS: Which Stock Is the Better Value Option?

Pacira's (PCRX) Q1 Earnings Top Estimates, Revenues Rise Y/Y

by Zacks Equity Research

Pacira (PCRX) beats on both earnings and revenues in the first quarter of 2020. The company temporarily suspends 2020 guidance in the wake of the COVID-19 pandemic.

Pacira (PCRX) Q1 Earnings and Revenues Top Estimates

by Zacks Equity Research

Pacira (PCRX) delivered earnings and revenue surprises of 65.62% and 4.52%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Pacira (PCRX) to Report Q1 Results: Wall Street Expects Earnings Growth

by Zacks Equity Research

Pacira (PCRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

PCRX or CTLT: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

PCRX vs. CTLT: Which Stock Is the Better Value Option?

Pacira (PCRX) Down 37.2% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Pacira (PCRX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.